Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …

BACKGROUND Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies
in England and Wales. Differentiated thyroid cancer (DTC) accounts for≈ 94% of all thyroid …

The number of thyroid cancers is increasing. Standard treatment usually includes primary
surgery, thyroid-stimulating hormone suppressive therapy, and ablation of the thyroid …

Vandetanib is a once-daily orally available tyrosine kinase inhibitor that works by blocking
RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR …

Cabozantinib is an oral once-daily multitarget tyrosine kinase inhibitor of MET, VEGFR2,
RET, acting against KIT, AXL, FLT3 and Tie-2. Cabozantinib has shown anti-cancer effects …

Background and Objective: Lenvatinib is an oral, multitargeted Tyrosine Kinase Inhibitor
(TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR1-VEGFR3), fibroblast growth …

The published result related to a phase II clinical study in Philadelphia illustrated treating
metastatic thyroid cancer patients with the targeted therapy of Vemurafenib to establish the …

Medullary thyroid cancer (MTC) is the third most frequent thyroid cancer arising from thyroid
parafollicular cells. Surgery is the first-line strategy in treatment of MTC but disease relapse …

Dal 2005, sono stati impiegati diversi tipi di inibitori multitarget delle tirosin-chinasi in studi
clinici per il trattamento di pazienti con carcinomi tiroidei in fase avanzata. Studi sperimentali …